Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 27: 574-579, 1981;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boyd, J. C.
Right arrow Articles by Ladenson, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyd, J. C.
Right arrow Articles by Ladenson, J. H.

Clinical Chemistry, Vol 27, 574-579, Copyright © 1981 by American Association for Clinical Chemistry

Parathyrin measured concurrently with free or total calcium in the differential diagnosis of hypercalcemia

JC Boyd, JW Lewis, E Slatopolsky and JH Ladenson

We assessed the diagnostic utility of measuring C-terminal immunoreactive parathyrin (i-PTH) concurrently with free (CaF) or total (CaT) calcium in four groups of patients: (1) 91 patients with histologically proven primary hyperparathyroidism; (2) seven patients without histological evidence of hyperparathyroidism; (3) 70 patients with non-parathyroid malignancies with hypercalcemia; and (4) 28 similar patients without hypercalcemia. In patients in Group 1, the use of either calcium measurement along with i-PTH increased diagnostic accuracy from 95 to 99%. In Group 2, values consistent with primary hyperparathyroidism were obtained for 21% of samples with i-PTH assay alone, 29% with i-PTH and CaT, and 12% with i-PTH and CaF. Surprisingly, 36% of samples from both malignancy groups (3 and 4) had above-normal i-PTH values. In patients with malignancy and hypercalcemia (Group 3) the following percentages were classified as possibly being hyperparathyroid: 26% with i-PTH assay alone; 31% with i- PTH and CaT, and 24% with i-PTH and CaF. Our data indicate that (a) about a fourth of patients with nonparathyroid malignancies also have evidence of hyperparathyroidism as judged by this (and probably all other) i-PTH methods based on C-terminal antibody specificity and that (b) measuring CaF and i-PTH rather than CaT and i-PTH gives a small increase in diagnostic accuracy.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American Association for Clinical Chemistry.